The FDA has approved two Ziihera (zanidatamab-hrii) regimens for first-line HER2-positive advanced gastroesophageal adenocarcinoma, offering significant survival gains over trastuzumab-based therapy.

Significantly lower all-cause infection rate seen in children receiving daily zinc supplementation versus placebo ...

The FDA requires an additional 3 months to review a major amendment to the Biologics License Application for deramiocel, ...

Investigational siRNA therapeutic targeting prekallikrein receives FDA Fast Track designation following promising phase 1/2 data in HAE.

Subcutaneous autoinjector formulation expands starting treatment options for mild cognitive impairment and mild dementia due ...

One phlebotomist can oversee up to 3 Aletta machines, directly helping to address the current phlebotomist shortage and long ...

On average, onset is 2.5 years earlier compared with nonusers, but differences increase with age. HealthDay News — Cannabis users may have an earlier age at onset (AAO) of psychosis than nonusers, ...

Avulux is the first FDA-authorized precision optical filter indicated to help manage light sensitivity associated with ...

Of the 1,357 AI devices authorized by the FDA, only three had evidence of clinical effectiveness and only 34 had registered clinical trials ...

HealthDay News — Combining chemotherapy with immunotherapy before surgery for head and neck cancer is associated with significantly greater reductions in tumor size than immunotherapy alone, according ...

Rate increased sharply after press release announcing leucovorin label would be updated to include cerebral folate deficiency.

While study did not reveal a causal link, authors advise reducing exposure, particularly to products with fragrances.